02 October 2008
Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke: preliminary experience
M. Fared K. SuriADEF, Haitham M. HusseinBCE, Mohamed M. AbdelmoulaBC, Afshin A. DivaniEG, Adnan I QureshiADEFMed Sci Monit 2008; 14(10): PI39-44 :: ID: 869394
Abstract
Background
There is a high risk of recurrence within the first 72 hours of ischemic stroke. Without bolus, the peak effect of clopidogrel may be delayed for 72 hours. A bolus may shorten this time but its safety in acute ischemic stroke is unknown.
Material and Method
All patients with acute ischemic stroke or transient ischemic attack within a 10 month period were administered 600 mg clopidogrel bolus if they were already taking aspirin regularly, or had aspirin allergy or intolerance. Demographic data, duration to initiation of therapy, National Institute of Health Stroke Scale score (NIHSSS) at baseline and at 24 hours were collected. Brain imaging studies were reviewed for hemorrhagic transformation. Wilcoxin rank sum test was used for comparison of NIHSSS over time.
Results
A total of 20 patients (mean age 66+/-14, men n=8) were loaded with clopidogrel because of aspirin failure (n=16), aspirin allergy (n=1), aspirin intolerance secondary to gastritis (n=2) or stent placement in the setting of acute stroke (n=1). Median time interval between clopidogrel bolus and symptom onset was 25 hours. The median NIHSSS at 24 hours (1, range 0-15) was significantly (p<0.01) lower than the NIHSSS at baseline (3, range 0-24). Neurological deterioration (NIHSSS increase > or =4 points) or hemorrhagic transformation was not seen in any patient.
Conclusions
A 600 mg clopidogrel bolus prior to initiating regular dose clopidogrel in the setting of acute ischemic stroke was safe. The potential for risk reduction in early recurrent stroke needs to be studied in future studies.
Keywords: Stroke - prevention & control, Recurrence, Prospective Studies, Platelet Aggregation Inhibitors - therapeutic use, Brain Ischemia - prevention & control, Aspirin - therapeutic use, Ticlopidine - therapeutic use, Aged, 80 and over
Editorial
01 April 2024 : Editorial
Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection – Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug ResistanceDOI: 10.12659/MSM.944600
Med Sci Monit 2024; 30:e944600
In Press
21 Mar 2024 : Meta-Analysis
Economic Evaluation of COVID-19 Screening Tests and Surveillance Strategies in Low-Income, Middle-Income, a...Med Sci Monit In Press; DOI: 10.12659/MSM.943863
10 Apr 2024 : Clinical Research
Predicting Acute Cardiovascular Complications in COVID-19: Insights from a Specialized Cardiac Referral Dep...Med Sci Monit In Press; DOI: 10.12659/MSM.942612
06 Mar 2024 : Clinical Research
Enhanced Surgical Outcomes of Popliteal Cyst Excision: A Retrospective Study Comparing Arthroscopic Debride...Med Sci Monit In Press; DOI: 10.12659/MSM.941102
06 Mar 2024 : Clinical Research
Prevalence and Variation of Medical Comorbidities in Oral Surgery Patients: A Retrospective Study at Jazan ...Med Sci Monit In Press; DOI: 10.12659/MSM.943884
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952